XERSXeris Biopharma Holdings, Inc.

$982M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+132.7% YoY

Gross Profit

$261,00014.0% margin

Operating Income

-$33M-1759.7% margin

Net Income

-$33M-1774.8% margin

EPS (Diluted)

$-1.23

QoQ Revenue Growth

+477.1%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$109M

Total Liabilities

$95M

Stockholders' Equity

$14M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$801,000	+132.7%
Gross Profit	$261,000	$759,000	-65.6%
Operating Income	-$33M	-$20M	-61.5%
Net Income	-$33M	-$20M	-62.0%

XERS Q4 2019 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena